Revised: April 2000
Trimethoprim is a synthetic antibacterial available in tablet form for oral administration.
Trimethoprim (trimethoprim) is indicated for the following:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Trimethoprim Tablets USP and other antibacterial drugs, Trimethoprim Tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus.
Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.
Media Articles Related to Trimethoprim
Childhood Urinary Tract Infection May Bring Lasting Harm to Kidneys
Source: MedicineNet Kidney Failure Specialty [2014.08.06]
Title: Childhood Urinary Tract Infection May Bring Lasting Harm to Kidneys
Category: Health News
Created: 8/5/2014 2:36:00 PM
Last Editorial Review: 8/6/2014 12:00:00 AM
Identifying kids and teens with kidney damage risk after 1st urinary tract infection
Source: Urology / Nephrology News From Medical News Today [2014.08.05]
Children and adolescents with an abnormal kidney ultrasonography finding or with a combination of a fever of at least 102 degrees and infection with an organism other than E.
Urinary Tract Infections (UTIs)
Source: MedicineNet Abdominal Pain Specialty [2014.06.12]
Title: Urinary Tract Infections (UTIs)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/12/2014 12:00:00 AM
Urinary Tract Infections and Menopause
Source: MedicineNet Urinary Incontinence Specialty [2014.06.06]
Title: Urinary Tract Infections and Menopause
Category: Ask The Experts
Created: 11/27/2006 12:00:00 AM
Last Editorial Review: 6/6/2014 12:00:00 AM
Urinary Tract Infection in Adults Quiz
Source: MedicineNet amoxicillin and clavulanic acid Specialty [2014.02.28]
Title: Urinary Tract Infection in Adults Quiz
Category: MedicineNet Quiz
Created: 6/10/2010 12:17:00 PM
Last Editorial Review: 2/28/2014 1:19:24 PM
Published Studies Related to Trimethoprim
Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. [2011.07.08]
BACKGROUND: The ACT recommended by WHO is very effective and well-tolerated. However, these combinations need to be administered for three days, which may limit adherence to treatment.The combination of dihydroartemisinin-piperaquine phosphate-trimethoprim (Artecom(R), Odypharm Ltd), which involves treatment over two days, appears to be a good alternative, particularly in malaria-endemic areas. This study intends to compare the efficacy and tolerability of the combination dihydroartemisinin-piperaquine phosphate-trimethoprim (DPT) versus artemether-lumefantrine (AL) in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal... CONCLUSION: The overall efficacy and tolerability of DPT are similar to those of AL. The ease of taking DPT and its short treatment course (two days) may help to improve adherence to treatment. Taken together, these findings make this medicinal product a treatment of choice for the effective management of malaria in Africa.
Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. [2010.09]
STUDY OBJECTIVE: Community-associated methicillin-resistant Staphylococcus aureus is now the leading cause of uncomplicated skin abscesses in the United States, and the role of antibiotics is controversial. We evaluate whether trimethoprim-sulfamethoxazole reduces the rate of treatment failures during the 7 days after incision and drainage and whether it reduces new lesion formation within 30 days... CONCLUSION: After the incision and drainage of uncomplicated abscesses in adults, treatment with trimethoprim-sulfamethoxazole does not reduce treatment failure but may decrease the formation of subsequent lesions. Copyright (c) 2010 American College of Emergency Physicians. Published by Mosby, Inc. All rights reserved.
Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. [2010.07.15]
BACKGROUND. Although the use of antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) is largely accepted, controversy remains regarding whether the choice of antibiotic has any impact on outcome.
Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. [2010.07]
Various infectious agents, such as Toxoplasma gondii, have been hypothesized to be potentially relevant etiological factors in the onset of some cases of schizophrenia. We conducted a randomized, double-blind, placebo-controlled treatment trial in an attempt to explore the hypothesis that the symptoms of schizophrenia may be related to infection of the central nervous system with toxoplasma gondii...
Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated
skin abscesses in patients at risk for community-associated methicillin-resistant
Staphylococcus aureus infection. 
within 30 days... CONCLUSION: After the incision and drainage of uncomplicated abscesses in adults,
Clinical Trials Related to Trimethoprim
A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS [Completed]
To evaluate the effectiveness of two oral treatments for mild to moderate Pneumocystis
carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a
standard treatment program of sulfamethoxazole/trimethoprim (SMX/TMP) to assess the tolerance
of these two alternative treatments as compared to the standard treatment of SMX/TMP. Per
09/09/92 amendment, to assess the efficacy and tolerance of these two alternative treatments
in patients who are intolerant to SMX/TMP.
The type of treatment being studied has the advantages of wide applicability throughout the
world (including developing countries) and low cost. An oral treatment is more accessible to
patients than drugs given by injection or by inhalation.
The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa [Completed]
The purpose of this study is to assess the efficacy of trimethoprim in promoting wound
healing and decreasing blister formation in patients with Epidermolysis Bullosa.
Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations [Recruiting]
This study will find how weight affects the dosing of a drug called sulfamethoxazole and
trimethoprim. Currently, the amount of sulfamethoxazole and trimethoprim a patient receives
is the same regardless of the patient's weight.
All sulfamethoxazole and trimethoprim (Trade name is Bactrim or Septra) medication that you
will receive in this study will be referred to as study medication within this informed
consent form. This drug is a combination of two antibiotics, sulfamethoxazole and
trimethoprim, which belongs to a class of medication known as "sulfones" and is approved by
the US Food and Drug Administration (FDA) for the treatment of a wide variety of bacterial
infections such as ear infections, urinary tract infections, bronchitis, traveler's
diarrhea, and Pneumocystis carinii pneumonia. Sulfamethoxazole and trimethoprim is given
Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS [Completed]
To compare the safety and effectiveness of an investigational drug therapy (trimetrexate plus
leucovorin calcium) with that of conventional therapy (sulfamethoxazole-trimethoprim) in the
treatment of moderately severe Pneumocystis carinii pneumonia (PCP) in patients who have
AIDS, are HIV positive, or are at high risk for HIV infection. New treatments are needed to
reduce the mortality rate from PCP in AIDS patients and to reduce the high relapse rate found
after conventional therapy. Trimetrexate (TMTX) was chosen for this trial because it was
found to be much more potent than sulfamethoxazole/trimethoprim (SMX/TMP) against the PCP
organism in laboratory tests. Also TMTX, in combination with leucovorin (LCV), did not cause
severe toxicity in a preliminary trial. It is believed that TMTX will be more effective in
treating PCP and in preventing a recurrence of PCP.
Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients [Recruiting]
Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis
carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD)
treated with high-dose glucocorticoids and immunosuppressive agents.
Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12
Reports of Suspected Trimethoprim Side Effects
Diabetes Mellitus (47),
Cardiac Murmur (47),
Urinary Tract Infection (47),
Sinus Tachycardia (47),
Body Mass Index Decreased (46),
Abdominal Tenderness (46),
White Blood Cell Count Increased (46), more >>